Orthocell Ltd, a regenerative medicine company listed on the Australian Stock Exchange (ASX:OCC), has successfully raised $30.0 million in investment capital from investors. This funding round marks a significant milestone for the company, which is dedicated to developing breakthrough products that harness the human body's natural healing capabilities to restore mobility, function, and performance.
Orthocell's focus is on developing a portfolio of regenerative medical products and devices, including autologous cell therapies and collagen medical devices manufactured in Perth, Western Australia, using the proprietary SMRT™ process. Key products include Remplir™, a sterile, resorbable collagen nerve wrap used for peripheral nerve injuries; Striate+™, a collagen membrane for dental surgery distributed globally via BioHorizons; and SmrtGraft™, a collagen scaffold for tendon repair. The company also offers personalised cell therapies such as OrthoACI™ for cartilage regeneration and OrthoATI™ for chronic tendon injuries, both utilising a patient's own healthy cells.
The $30.0 million capital injection is poised to accelerate Orthocell's strategic objectives. The funds are expected to support ongoing research and development initiatives, advance the commercialization of its regenerative medicine product pipeline, and facilitate expansion into new global markets. This investment underscores confidence in Orthocell's technology and its potential to address unmet medical needs in regenerative medicine, enabling the company to scale its operations and bring its innovative therapies to a broader patient base.
Looking ahead, this funding positions Orthocell to further its mission of delivering innovative regenerative solutions to patients worldwide. The company aims to enhance patient outcomes, strengthen its market position, and solidify its leadership in the rapidly evolving regenerative medicine sector.
